SoftBank Vision Fund 2, Itochu and an unnamed insurer took part in a series C round that hiked the gene and cell therapy developer's total funding to $845m.
US-based gene therapy developer ElevateBio secured $525m yesterday in a series C round that included telecommunications and internet group SoftBank’s Vision Fund 2 and diversified trading firm Itochu.
The round was led by investment manager Matrix Capital Management and also featured investment and financial services group Fidelity Management & Research Company in addition to a large undisclosed insurance firm.
MPM Capital, F2 Ventures, Redmile Group, EcoR1 Capital, Samsara BioCapital, The Invus Group, Emerson Collective, Surveyor Capital, EDBI and Vertex Ventures…
